Sarah E. Dorff

Whole-genome association study identifies STK39 as a hypertension susceptibility gene

Sanjiv J. Shah, J. O’Connell, A. Chakravarti, 2009, Proceedings of the National Academy of Sciences.

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Richard Pazdur, Robert Justice, Nitin Mehrotra, 2015, Clinical Cancer Research.

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Sarah E. Dorff, K. Goldberg, R. Pazdur, 2019, Clinical Cancer Research.

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

Sarah E. Dorff, Amy McKee, R. Pazdur, 2016, Clinical Cancer Research.

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

Sarah E. Dorff, R. Pazdur, R. Charlab, 2020, Clinical Cancer Research.

FDA Approval Summary: Belzutifan for von Hippel-Lindau disease associated tumors.

Sarah E. Dorff, Martha Donoghue, R. Pazdur, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Sarah E. Dorff, L. Fashoyin-Aje, K. Goldberg, 2020, Clinical Cancer Research.

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Sarah E. Dorff, K. Goldberg, R. Pazdur, 2020, Clinical Cancer Research.